Literature DB >> 15648057

[18F]FDOPA PET and clinical features in parkinsonism due to manganism.

Brad A Racette1, Jo Ann Antenor, Lori McGee-Minnich, Stephen M Moerlein, Tom O Videen, Vikas Kotagal, Joel S Perlmutter.   

Abstract

Manganese exposure reportedly causes a clinically and pathophysiologically distinct syndrome from idiopathic Parkinson's disease (PD). We describe the clinical features and results of positron emission tomography with 6-[18F]fluorodopa ([18F]FDOPA PET) of a patient with parkinsonism occurring in the setting of elevated blood manganese. The patient developed parkinsonism associated with elevated serum manganese from hepatic dysfunction. [18F]FDOPA PET demonstrated relatively symmetric and severely reduced [18F]FDOPA levels in the posterior putamen compared to controls. The globus pallidum interna had increased signal on T1-weighted magnetic resonance imaging (MRI) images. We conclude that elevated manganese exposure may be associated with reduced striatal [18F]FDOPA uptake, and MRI may reveal selective abnormality within the internal segment of the pallidum. This case suggests that the clinical and pathophysiological features of manganese-associated parkinsonism may overlap with that of PD. Copyright 2005 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15648057     DOI: 10.1002/mds.20381

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  26 in total

Review 1.  Neuroimaging biomarkers for Parkinson disease: facts and fantasy.

Authors:  Joel S Perlmutter; Scott A Norris
Journal:  Ann Neurol       Date:  2014-11-07       Impact factor: 10.422

2.  Effects of chronic manganese exposure on cognitive and motor functioning in non-human primates.

Authors:  Jay S Schneider; Emmanuel Decamp; Amy Jo Koser; Stephanie Fritz; Heather Gonczi; Tore Syversen; Tomás R Guilarte
Journal:  Brain Res       Date:  2006-09-15       Impact factor: 3.252

Review 3.  Are there common biochemical and molecular mechanisms controlling manganism and parkisonism.

Authors:  Jerome A Roth
Journal:  Neuromolecular Med       Date:  2009-09-16       Impact factor: 3.843

4.  Neuromythology of Manganism.

Authors:  Kristin M Andruska; And Brad A Racette
Journal:  Curr Epidemiol Rep       Date:  2015-06

5.  Prolactin levels in manganese-exposed male welders.

Authors:  Engin Tutkun; Sedat Abuşoğlu; Hinç Yılmaz; Meşide Gündüzöz; Nilgün Gıynas; Ceylan Demir Bal; Ali Ünlü
Journal:  Pituitary       Date:  2014-12       Impact factor: 4.107

6.  Pathophysiology of manganese-associated neurotoxicity.

Authors:  Brad A Racette; Michael Aschner; Tomas R Guilarte; Ulrike Dydak; Susan R Criswell; Wei Zheng
Journal:  Neurotoxicology       Date:  2011-12-21       Impact factor: 4.294

7.  [18F]FDOPA positron emission tomography in manganese-exposed workers.

Authors:  Susan R Criswell; Susan Searles Nielsen; Mark Warden; Joel S Perlmutter; Stephen M Moerlein; Hubert P Flores; John Huang; Lianne Sheppard; Noah Seixas; Harvey Checkoway; Brad A Racette
Journal:  Neurotoxicology       Date:  2017-07-08       Impact factor: 4.294

8.  Impact of repeated topical-loaded manganese-enhanced MRI on the mouse visual system.

Authors:  Shu-Wei Sun; Tiffany Thiel; Hsiao-Fang Liang
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-07-12       Impact factor: 4.799

Review 9.  Manganese and Parkinson's disease: a critical review and new findings.

Authors:  Tomás R Guilarte
Journal:  Environ Health Perspect       Date:  2010-04-19       Impact factor: 9.031

10.  The effect of manganese on dopamine toxicity and dopamine transporter (DAT) in control and DAT transfected HEK cells.

Authors:  Jerome A Roth; Zhezheng Li; Swetha Sridhar; Habibeh Khoshbouei
Journal:  Neurotoxicology       Date:  2013-01-11       Impact factor: 4.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.